Nurturing Health, Naturally Controlling Sugar – GlycoBioPro Lactotech
As a bright star in the field of biotechnology created by AFMU-China team, we unswervingly adhere to the corporate vision of "science and technology leading the healthy course, innovation and casting the quality of life", deeply cultivate the cross-integration field of microbial science and biological engineering technology, and constantly explore and make breakthroughs. In the context of today's fast-paced society, health has become an indispensable and valuable wealth for people, especially in the face of the global challenges of diabetes and its metabolic diseases, we know the importance and urgency of providing safe, efficient and sustainable health management programs.
This project is rooted in the urgent research and development needs of diabetes treatment drugs, the internal impetus of the industry development and the strong support of national policies. We focus on the cutting-edge research and development and application of engineered lactic acid bacteria, adopt the innovative mode of deep integration of industry, university and research, and lead the scientific research direction by enterprises to ensure the rapid transformation of scientific research achievements into industrial power. Our goal is to improve the research and development level of engineered lactic acid bacteria, ensure the excellent quality of products, actively fulfill social responsibilities, and deepen the cooperation network, aiming to become a global leader in the research and development of diabetes treatment drugs, and make an important contribution to the global health cause.
At the core technology level, we have mastered the innovative technology of engineered lactic acid bacteria, and continue to build a perfect design platform to provide customers with customized engineered lactic acid bacteria products covering the two major fields of drugs and dairy products. Our advantages lie in professional excellence, mature and stable technology, independent control of core technology, excellent product quality, and strong research and development strength. Further, we rely on the frontier gene testing technology, for individual genetic differences, provide accurate health management scheme, realize global drug development, sales and health monitoring of one-stop service, build up from the source to terminal application, to the effect evaluation of closed loop health management system, bring users more personalized, efficient and secure health experience.
In terms of business operation, we flexibly adopt various business models such as direct sales, customization, membership, authorization and platform, integrate online and offline interaction, and promote the extensive circulation and in-depth communication of products and services. Looking forward to the future, we will continue to expand the service scope, enhance the brand influence, and lead the new fashion of the industry development.
In terms of team management, we follow the principles of modern corporate governance, implement flat management, scientifically allocate human resources, continuously optimize the talent structure, and lay a solid foundation for the continuous innovation and development of the enterprise.
In terms of financing, we rely on multi-channel financing strategies such as angel investment, venture capital and strategic investment. At the same time, we strengthen business cooperation, expand service areas, constantly enhance the value of enterprises, and provide solid support for long-term development.
In the face of risks and challenges, we have formulated a comprehensive response strategy, covering legal regulation, market competition, technical services, human resources and clinical trials and other dimensions, to ensure the steady progress of enterprises, and to provide exit channels for capital at an appropriate time.
Adhering to the core concept of "probiotic sugar, natural health", we will continue to innovate, pursue excellence, take science and technology as the wing, health as the soul, and have the courage to face future challenges, sincerely serve the public, to improve the quality of human life and promote the development of the field of diabetes treatment.
In the context of the big health industry, GlycoBioPro Lactotech has emerged, focusing on the development of innovative products that can accurately act in the field of blood glucose regulation and metabolic health. We are committed to combining the international cutting-edge synthetic biology research results with the actual needs of the domestic market, through scientific formula design and strict production process, to create a series of high quality and high safety of engineered lactic acid bacteria drugs and functional food.
In the process of product research and development, we always adhere to a scientific and rigorous attitude, establish close cooperation relations with many well-known scientific research institutions at home and abroad, and jointly explore the infinite possibilities of synthetic biology in the field of health management. We are well aware that behind each product are numerous experimental validation and data analysis, and only engineered strains that are rigorously screened and evaluated for clinical evaluation can be applied to our products to ensure real health benefits to consumers.
At the same time, we also deeply realize that the market demand is the fundamental driving force for the development of enterprises. Therefore, while in product research and development, we also actively pay attention to the market dynamics and consumer demand changes. Through market research and data analysis, we constantly optimize the product portfolio and marketing strategy to ensure that our products can accurately meet the market demand and win the trust and praise of consumers.
Looking forward to the future, The company will continue to adhere to the core concept of "probiotics control sugar, natural health", and is committed to becoming a leading enterprise in the field of blood glucose regulation and metabolic health. We will continue to increase the investment in research and development, deepen the scientific research cooperation, expand the product lines, enhance the brand influence, and contribute our strength to the cause of public health. At the same time, we also look forward to working with more like-minded partners to create a bright future of health technology.
The global epidemic of diabetes is becoming increasingly severe. According to the latest authoritative estimate, the number of diabetes patients worldwide has exceeded the 400 million mark. This alarming number is still rising at an alarming rate, highlighting the huge challenges facing the global public health field. With the continuous expansion of the patient base, the demand for efficient, safe and patient-friendly diabetes treatment drugs has also increased sharply, becoming a powerful driving force for the field of pharmaceutical research and development.
In China, as the hardest hit area of global diabetes patients, the potential of its diabetes drug market is immeasurable. In recent years, the size of Chinas diabetes drug market has maintained a steady growth trend, which not only reflects the urgent demand of domestic patients for treatment methods, but also provides unprecedented development opportunities for domestic and foreign pharmaceutical enterprises. This huge market space undoubtedly lays a broad road for the research and development and innovation of new diabetes drugs, and inspires researchers to constantly explore and make breakthroughs, in order to bring safer, more effective and convenient treatment choices for patients.
However, although the existing drugs for diabetes treatment have alleviated the disease to some extent, their limitations can not be ignored. Although insulin therapy is a classic therapy, the frequent injection process undoubtedly increases the physical and mental burden of patients; while oral hypoglycemic drugs are easy to take, but often accompanied by gastrointestinal discomfort and hypoglycemia, which affect the quality of life of patients.Therefore, the development of new diabetes drugs that can overcome these limitations and achieve safer and more safe, effective and convenient treatment has become an urgent need and an important topic in the current medical field.
With the rapid progress of modern biotechnology and high-precision gene sequencing technology, the treatment strategy of diabetes is undergoing a profound change and moving towards a more accurate and personalized direction. Scientists were able to explore complex factors such as genetic information, metabolic pathways and even the microbiome to reveal individual differences in the pathogenesis of diabetes, drug response and risk of complications. Based on these insights, drug development is gradually shifting to customized models to develop new drugs that can target each patients unique and physiological state and therapeutic needs. This personalized treatment strategy is not only expected to significantly improve the treatment effect, accurately control the blood sugar level, but also can effectively reduce the unnecessary side effects brought by traditional drugs, and improve the quality of life and treatment satisfaction of patients.
In the context of the current pharmaceutical industry, the research and development and marketing of new diabetes drugs have been significantly accelerated, and they have become an important force to promote the innovation and development of the industry. With the expanding global base of diabetic patients, there is an urgent need for efficient, safe and personalized treatment solutions. In this context, many pharmaceutical enterprises have increased investment in research and development, using advanced biotechnology, gene sequencing and other means to constantly explore new drug targets and mechanisms, and successfully launched a series of innovative diabetes drugs. These new drugs not only show excellent efficacy in glycemic control, but also effectively reduce side effects through precise treatment strategies, provide patients with more diversified and optimized treatment options, and further promote the prosperity and development of the field of diabetes treatment.
As the forefront of the pharmaceutical field, the research and development of new diabetes drugs has a far-reaching impact on far more than meeting the growing market demand. As a strong driving force, it leads the pharmaceutical industry to a higher level and promotes the upgrading and transformation of the whole industry. Through continuous technological innovation and product research and development, pharmaceutical enterprises can not only effectively solve the current pain points and problems in the treatment of diabetes, but also occupy a leading position in the global pharmaceutical market and build a strong core competitiveness. This sustainable development model based on innovation has not only brought long-term economic benefits to enterprises, but also promoted the common progress of the global medical and health cause, and made an important contribution to the human health and well-being of mankind.
In view of the major threat of diabetes to public health, the governments of all countries have promoted its prevention and treatment to the national strategic height, and introduced a series of incentive policies and supporting measures. These policies not only cover direct economic support such as financial subsidies and tax incentives, but also involve key links such as accelerated research and development approval and intellectual property protection, laying a green channel for the research and development of new diabetes drugs. The all-round policy escort not only reduces the risk of research and development, but also stimulates the innovation vitality of enterprises, and provides a solid backing and strong impetus for the rapid emergence of new diabetes drugs.
Through self-established e-commerce platforms and entered mainstream e-commerce platforms (such as Tmall, Jingdong, etc.), to realize direct sales of products, and develop a distributor network to cover a wider range of consumer groups. Distributors are not only limited to traditional pharmacies and health care products stores, but also include health management institutions and medical institutions, forming a multi-channel sales pattern.
Launch different specifications of package products to meet the needs and budget range of different consumers. At the same time, it provides customized services, and personalized engineering bacteria formula is designed according to the specific conditions of patients (such as blood glucose level, intestinal flora analysis results, etc.) to improve the added value of products and customer stickiness.
Establish a membership system to provide members with regular one-stop services such as product distribution, health consultation, health management plan, etc. Members can choose different levels of service packages according to their own needs, and enjoy exclusive discounts and personalized care.
Use smart wearable devices, mobile APP and other tools to collect users health data (such as blood glucose monitoring, exercise records, etc.), and provide users with personalized health suggestions and product recommendations through data analysis. At the same time, provide regular feedback on health improvement to users to enhance user engagement and trust.
Conduct online courses and training such as diabetes health education, nutrition lectures, and engineering bacteria knowledge popularization to attract the participation of potential users and existing users. Enhance brand image and user loyalty through education marketing, while creating additional revenue streams for enterprises.
Establish cooperative relations with hospitals, clinics and other medical institutions to provide auxiliary treatment programs for engineering bacteria products for diabetic patients. Expand the use scope and influence of the products through the doctors recommendations and prescriptions.
Conduct joint research and development projects with universities, scientific research institutions and pharmaceutical enterprises to jointly promote the transformation of scientific research achievements in diabetes-related fields. The value of intellectual property rights is maximized by means of technology transfer and patent authorization.
Integrate upstream and downstream resources to build a complete industrial chain from strain selection, production and processing to marketing. Improve overall profitability by optimizing production processes, reducing costs, and improving product quality and efficiency.
Promote GlycoBioPro Lactotech series of sugar-lowering products to the international market by participating in international exhibitions and establishing overseas sales channels. Product adjustment and marketing strategy optimization for different countries and regions regulations, culture and market needs, so as to realize the global layout and income diversification.
Strengthen exchanges and cooperation with international counterparts, introduce advanced technology and management experience, and enhance the international competitiveness and brand influence of enterprises. At the same time, through international cooperation projects to expand new business areas and market space.
Using the cutting-edge foodborne induced secretion strategy, the engineered strains can accurately sense the changes in postprandial blood glucose levels, and timely release therapeutic molecules when blood glucose naturally rises. This intelligent regulatory mechanism not only improves the pertinence of the therapeutic effect, but also significantly reduces the release of drugs when not necessary, and reduces the potential interference with normal blood glucose levels.
By precisely regulating the expression of therapeutic molecules, our engineered strains can achieve personalized treatment for diabetic patients. Compared with the traditional method, this precision treatment method is more delicate, which can better meet the treatment needs of different patients and improve the overall satisfaction of the treatment effect.
The selection of lactococcus lactis as a chassis cell ensures the safety of therapeutic products based on its decades of safe use record in the food industry. The low immunogenicity of this strain further reduces the risk of immune response during patient use and improves the tolerance and comfort of treatment.
In the process of product development, we have conducted strict safety assessment, including strain toxicity testing, genetic stability analysis and long-term safety monitoring, to ensure the safety of the whole chain from development to application.
The large-scale cultivation technology of engineering strains is mature and controllable, which enables our therapeutic products to be available at a lower production cost. This not only helps to reduce the market price of products, improve the market competitiveness, but also brings higher profit space for enterprises.
Our engineered strain therapy products have a simpler distribution process than traditional drug therapy and insulin injection. Patients do not need to go to medical institutions frequently, but only need to use it according to the doctors advice, which greatly reduces the treatment cost and time cost of patients.
With a profound vision, it is committed to becoming an innovator in the field of diabetes management. We firmly believe that the deep integration of cutting-edge microbiome research and precision medicine technology will unlock a new chapter in diabetes treatment. The project aims to explore the complex interaction between intestinal microorganisms and diabetes, and develop personalized engineering bacteria and their derivative products with independent intellectual property rights, so as to regulate human metabolic balance, optimize blood glucose control, and reduce drug dependence and side effects.
Our goal is to make the health benefits of technology accessible to every person with diabetes. Through our efforts, the management of diabetes will become more scientific, convenient and humanized. We hope that the project will become a bridge connecting scientific research and clinical practice, promote the fundamental change of diabetes treatment mode, bring hope and light to diabetes patients around the world, and step towards a bright future of sugar-free life together.
GlycoBioPro Lactotech will uphold the "innovation leading, scientific rigorous, quality excellence, responsibility, open cooperation, integrity for this" the core values, pay close attention to the field of diabetes management market demand and competition pattern, continue to optimize our microbiome research and siege bacteria product development strategy, with science and technology power to protect public health, aims to become the global diabetes research of science and technology, realize the sustainable development of the enterprise and contribute significant social value.
GlycoBioPro Lactotech is committed to the exploration and application of cutting-edge technologies, constantly develops innovative engineering bacteria products, promotes the innovation of diabetes management with scientific innovation, and improves the quality of life of patients.
We adhere to the scientific spirit, based on rigorous experimental design and data analysis, ensure the scientific nature and effectiveness of each research result, and provide diabetes patients with scientific evidence based on health solutions.
Quality is our lifeline. GlycoBioPro Lactotech puts quality in the first place, establishes a high standard quality management system, to ensure the safety and effectiveness of each product, and to protect the health and trust of patients.
We are fully aware of the great social responsibility we shoulder, and actively participate in the prevention and control of diabetes and public health, contribute to global health through scientific and technological innovation, and contribute to the construction of a healthy society.
With the concept of openness and win-win, GlycoBioPro Lactotech will strengthen cooperation with domestic and foreign scientific research institutions, medical institutions and enterprises, share resources, make collaborative innovation, and jointly promote the progress and development of diabetes bacteria research technology.
Honesty is the cornerstone of our corporate culture. We adhere to the integrity of management, respect intellectual property rights, maintain a fair competition market environment, with good corporate reputation to win the trust and support from all walks of life.
Diabetes mellitus is a chronic disease caused by insufficient insulin secretion or action dysfunction, mainly characterized by persistent increases in blood glucose levels. Depending on the etiology and clinical manifestations, diabetes can be divided into multiple types, with the most common being type 1 diabetes and type 2 diabetes. Type 2 diabetes is even more common, and occurs mainly in adults, especially in middle-aged and older people. Its pathogenesis is complex, involving many factors such as genetics, environment and lifestyle. Insulin secretion may be normal or slightly higher, but the effect of insulin is reduced, that is, insulin resistance. As the disease develops, the function of islet β -cells gradually declines, insulin secretion decreases, and blood glucose levels further increase.
The effects of diabetes on the body are multifaceted. Long-term hyperglycemia can cause damage to multiple organs and systems throughout the body, including the cardiovascular system, nervous system, kidneys, eyes, etc. Cardiovascular disease is one of the most common complications in patients with diabetes, including coronary heart disease, myocardial infarction, stroke and so on. In addition, diabetes can also lead to neuropathy, such as peripheral neuropathy and autonomic neuropathy, with symptoms of limb numbness, pain, paresthesia and so on. Diabetic nephropathy is one of the serious complications of diabetes, which can lead to renal failure and uremia. Diabetic retinopathy may lead to visual loss or even blindness. Blood sugar regulation function disorder can directly affect the body function, which lead to the decline of systemic health level, and diabetes complications can cause a series of physiological and psychological symptoms (figure 1), lead to social embarrassment, depression and anxiety, seriously disturb the patients career and social life.
The incidence of diabetes mellitus is on the rise worldwide. According to the International Diabetes Federation (IDF), the number of diabetes patients worldwide has exceeded 400 million, and the number is still growing. However, due to the complex etiology of diabetes mellitus. Genetic factors, viral infection, chemical exposure, autoimmune responses, etc., can all lead to diabetes. In addition, the use of some drugs may also trigger diabetes, such as long-term use of drugs such as glucocorticoids. At present, there is still a lack of effective treatment means in clinical practice, and insulin injection and hypoglycemic drugs are still used as the main treatment means. However, long-term insulin injection will cause adverse reactions such as hypoglycemia or gastrointestinal discomfort in patients. Therefore, the use of non-invasive and low side effects is a more ideal treatment for diabetes.
The incidence of diabetes mellitus is on the rise worldwide. According to the International Diabetes Federation (IDF), the number of diabetes patients worldwide has exceeded 400 million, and the number is still growing. However, due to the complex etiology of diabetes mellitus. Genetic factors, viral infection, chemical exposure, autoimmune responses, etc., can all lead to diabetes. In addition, the use of some drugs may also trigger diabetes, such as long-term use of drugs such as glucocorticoids. At present, there is still a lack of effective treatment means in clinical practice, and insulin injection and hypoglycemic drugs are still used as the main treatment means. However, long-term insulin injection will cause adverse reactions such as hypoglycemia or gastrointestinal discomfort in patients. Therefore, the use of non-invasive and low side effects is a more ideal treatment for diabetes.
The incidence of diabetes mellitus is on the rise worldwide. According to the International Diabetes Federation (IDF), the number of diabetes patients worldwide has exceeded 400 million, and the number is still growing. However, due to the complex etiology of diabetes mellitus. Genetic factors, viral infection, chemical exposure, autoimmune responses, etc., can all lead to diabetes. In addition, the use of some drugs may also trigger diabetes, such as long-term use of drugs such as glucocorticoids. At present, there is still a lack of effective treatment means in clinical practice, and insulin injection and hypoglycemic drugs are still used as the main treatment means. However, long-term insulin injection will cause adverse reactions such as hypoglycemia or gastrointestinal discomfort in patients. Therefore, the use of non-invasive and low side effects is a more ideal treatment for diabetes.
In conclusion, the incidence of diabetes is high and increasing, which has adverse effects on patients health, and even systemic and mental health. However, due to its complex and diverse causes, the traditional treatment methods have not achieved good results. Therefore, it is urgent to find a treatment that can effectively control blood glucose to improve the quality of life and physical and mental health of diabetic patients.
The closed-loop insulin delivery system, also known as the artificial pancreas system, combines an insulin pump with a continuous blood glucose monitor to form a feedback loop. These systems can automatically adjust insulin administration according to real-time blood glucose levels, reducing the burden of diabetes management and improving overall glycemic control. As a product of modern medical technology, insulin pump provides more convenient and accurate insulin delivery methods for many patients with diabetes, and improves the quality of life of patients. At the same time, the closed-loop insulin delivery system can simulate the physiological function of the human pancreas, and automatically adjust the insulin injection dose according to the blood sugar level of the patient, realizing the precise control of blood sugar, and reducing the risk of hypoglycemia and hyperglycemia. This intelligent management method not only reduces the burden of patients, but also improves the treatment effect.
However, this innovative therapy also faces some challenges, most notably its high price and the inconvenience to carry in vitro. Medtronics MiniMed 780G and Tandems Control-IQ are typical examples of such systems. In terms of the price, the insulin pump is obviously more expensive than the traditional insulin injection method. This is undoubtedly a heavy burden for many patients with limited economic conditions. Therefore, how to make more patients can afford the treatment cost has become an urgent problem to be solved. On the other hand, the insulin pump needs to be carried in vitro and invasive, which limits the freedom of movement to some extent, and causes a certain psychological burden on the patient. For patients who need to go out frequently or do strenuous exercise, this is undoubtedly a big problem. Moreover, in vitro carriage increases the risk of lost or damaged equipment, further increasing the financial and psychological stress of patients. Solving relevant core technologies and producing accurate internal blood glucose monitoring with independent intellectual property rights can greatly reduce the cost of diabetes treatment and improve the treatment effect, benefiting the majority of diabetic patients in China.
In conclusion, the closed-loop insulin delivery system therapy can stimulate insulin secretion and fundamentally solve the diabetes complications, systemic and mental health problems caused by insufficient insulin secretion. The clinical application of this technology has been recognized by most professionals and patients. However, at present, there is still a lack of internal monitoring of blood sugar and precise drug administration in the domestic market, and it is urgent to conquer relevant core technologies and produce related products.
The company has developed a personalized engineered lactobacillus bacteria powder suitable for diabetes patients through synthetic biology. The engineered lactic acid bacteria can secrete FGF21 and P9 protein according to the changes in blood glucose concentration indirectly reflected by cholate, with stable secretion amount and stable protein intensity. It enables patients to timely adjust the secreted protein content and secretion time according to their own blood sugar concentration after eating, and patients can also operate independently according to their own blood sugar conditions in real time under the guidance of doctors. The engineering lactic acid bacteria powder developed by the company has a solid foundation in the early stage, has obvious advantages in the treatment of diabetes, and has broad application prospects in the domestic market, mainly as follows:
1) With a large group of diabetes in China, it needs a safe and reliable treatment method with both short-term and long-term efficacy.
2)The effectiveness of closed-loop insulin delivery system in the treatment of mouth mouth has been preliminarily verified, and it is very advantageous compared with traditional treatment methods.
3) General-purpose products are being designed and developed to further expand the application market of lingual nerve electrical stimulator.
4) On the basis of the application of the pre-treatment of diabetes, the engineering lactic acid bacteria powder suitable for long-term diabetes patients is being further developed, which broadens the application scenario of the engineering lactic acid bacteria powder.
This product to achieve long-term, non-invasive diabetes drug delivery way, choose food grade lactic acid bacteria as the chassis cell, it is not only a kind of human normal probiotics can long-term residence in intestinal intestinal environment, also can use daily fermentation food such as yogurt in a more comfortable and smaller psychological burden take hypoglycemic microorganisms.
The expressed protein mainly consists of three parts, namely, FGF21, SP (secreted peptide), and CPP (penetrating membrane peptide).
Because the foreign proteins will have a toxic effect on the engineered bacteria, affecting their long-term survival and protein secretion. Therefore, we designed the SP segment (signal peptide) to promote the protein secretion of lactic acid bacteria. This effect is achieved by membrane flipping, and under the action of peptidoglycan hydrolase (peptidoglycan hydrolase) on the membrane surface, the SP protein remains on the membrane surface and secrete the FGF21-CPP fusion protein.
Since the intestinal mucosal epithelium is composed of close junctions of intestinal columnar cells, general macromolecular proteins cannot pass through, but can only be actively transported and absorbed in the form of amino acids. Moreover, due to the limitation of intestinal polyproteases (such as trypsin), pH and other special environmental factors, the reliability, safety and efficiency of intestinal delivery proteins have always been a difficult problem. Through the integrated design of FGF21 and the CPP fusion protein mediating the intestinal epithelial transcytosis protein, we not only improved the overall stability of the fusion protein, but also this clathrin-mediated targeted transcytosis is more safe and reliable than the previous "intestinal transit" strategy that destroyed the integrity of the intestinal mucosal barrier.
Compared with traditional drug therapy, it has small side effects and is safe and reliable. Treatment with hypoglycemic drugs is not timely; and long-term insulin injections can cause intolerable side effects, such as hypoglycemia, headache, and gastrointestinal reactions. The engineered lactic acid bacteria secreted protein can be adjusted and controllable, and the personalized treatment in the acceptable range of patients avoids the occurrence of adverse reactions caused by excessive blood glucose reduction to the greatest extent, and is safer and more reliable than the traditional treatment.
In the treatment of type 2 diabetes, the FGF21 (fibroblast growth factor 21) secreted by human liver and the protein P9 (belongs to the peptidase S41A family) secreted from human probiotics Akk bacteria have great application prospects. FGF21 enhances its sensitivity to insulin by forming an FGF21- βKlotho-FGFR complex through circulating blood action on the adipocyte membrane surface. P9 protein stimulates the secretion of GLP-1 (glucagon-like peptide-1) and IL-6 (interleukin-6) and enhances insulin through the binding of ICAM-2 (intercellular adhesion molecule 2) receptors on the cell surface of intestinal secretory cells L cells. P9 and FGF21 cooperate by promoting insulin secretion and improving insulin resistance, respectively.
To achieve long-term, non-invasive diabetes drug delivery way, we choose food grade lactic acid bacteria as our chassis cells, it is not only a kind of human normal probiotics can long-term residence in intestinal intestinal environment, also can use daily fermentation food such as yogurt in a more comfortable and smaller psychological burden take hypoglycemic microorganisms.
The human body will have a significant peak of blood sugar in 30 to 60 minutes after a meal. In order to address this change, diabetic patients usually inject insulin before meals, and multiple injections will bring a series of physical and psychological problems. Long-term hypoglycemic drugs may lead to hypoglycemia symptoms, nausea, fatigue and even syncope due to their unstable slow-release performance. In view of the above two points, we designed a food-borne induced expression system in lactic acid bacteria, that is, bile secretion. With the increase of intestinal bile acid concentration, the promoter GroESL in plasmid A in engineered lactic acid bacteria. The expressed protein mainly consists of three parts, namely, FGF21, SP (secreted peptide), and CPP (penetrating membrane peptide).1) SP: Because the foreign proteins will have a toxic effect on the engineered bacteria, affecting their long-term survival and protein secretion. Therefore, we designed the SP segment (signal peptide) to promote the protein secretion of lactic acid bacteria. This effect is achieved by membrane flipping, and under the action of peptidoglycan hydrolase (peptidoglycan hydrolase) on the membrane surface, the SP protein remains on the membrane surface and secrete the FGF21-CPP fusion protein. 2) CPP: Since the intestinal mucosal epithelium is composed of close junctions of intestinal columnar cells, general macromolecular proteins cannot pass through, but can only be actively transported and absorbed in the form of amino acids. Moreover, due to the limitation of intestinal polyproteases (such as trypsin), pH and other special environmental factors, the reliability, safety and efficiency of intestinal delivery proteins have always been a difficult problem. Through the integrated design of FGF21 and the CPP fusion protein mediating the intestinal epithelial transcytosis protein, we not only improved the overall stability of the fusion protein, but also this clathrin-mediated targeted transcytosis is more safe and reliable than the previous "intestinal transit" strategy that destroyed the integrity of the intestinal mucosal barrier.
It is far from enough for patients with type II diabetes to regulate blood glucose only after meals due to insulin resistance, and their elevated baseline level of blood glucose will also lead to a series of target organ damage. So we further designed the system for constitutive expression and displaying P9 protein on the membrane surface as a supplement to the hypoglycemic effect of FGF21. Under normal circumstances, most intestinal probiotics cannot no direct contact with intestinal epithelial cells due to the presence of the intestinal mucus layer. In diabetic patients, the intestinal mucus barrier becomes thin and it is damaged, which provides a theoretical basis for the interaction between the surface display protein of our lactobacillus membrane and intestinal cells. And the efficiency of constitutive expression protein in lactic acid bacteria is much lower than inducible expression, but due to the design of membrane display mode, constitutive expression of P9 protein can be continuously anchored to the membrane surface, to ensure the surface of lactobacillus also has a higher number of P9 protein and increased contact with intestinal L cell ICAM-2 receptor. The system also deacts after the improvement of intestinal mucosal status in diabetic patients due to the particularity of the parasitic site of lactic acid bacteria.
After the completion of product development and preliminary clinical trials, further large-scale clinical trials will be conducted to verify the long-term efficacy and safety of the product. At the same time, it is necessary to promote the products and establish sales channels to promote the products to major hospitals and clinics across the country, so as to bring convenience to the treatment of diabetic patients. For primary medical institutions, the threshold of use is lowered and general equipment is designed so that patients can use it by themselves. Through design, research and development and outsourcing services, the company has developed mature products, enjoy the scale benefits and network association advantages of technology enterprises, and provides high-quality engineering lactic acid bacteria. Through marketing activities, we will deepen peoples understanding of diabetes and treatment methods, improve the visibility and reputation of the products and the company, and further open up the market.
In the clinical trials, the product was further optimized and improved. In this process, we can communicate with doctors and patients to learn about their feedback and suggestions, and improve the treatment effect and user experience of the product.
Large-scale clinical trials are a necessary step to verify the long-term efficacy and safety of the product. In cooperation with several hospitals and clinics, the company has conducted large-scale clinical trials and collected clinical data, and analyzed these data to comprehensively and objectively evaluate the treatment effect and safety of the product, while providing a basis for the optimization and improvement of subsequent products.
First, cooperate with hospitals and clinics to establish sales channels and promote products to more medical institutions and patients. Publicity and promotion activities can be carried out online and offline. For example, through social media platforms such as wechat, QQ and Weibo, academic conferences and lectures are held offline, so as to attract more doctors and patients to understand and use the product.
Marketing is an important means to promote products. We can improve the popularity and reputation of our products by participating in industry exhibitions, releasing press releases, and making publicity videos. At the same time, we can also cooperate with enterprises in other related industries, such as probiotic yogurt companies, to launch co-brands and joint publicity to expand the market share.
After completing the expansion of the domestic market, we can further explore the international market and promote the products to the global scope. We can consider cooperating with overseas hospitals and medical institutions to promote the product, and carry out relevant market research and product adaptability test, to improve the product competitiveness and brand influence, and further expand the market share.
Strengthen technological innovation and professional and technical personnel training, further explore and develop new treatment methods and products, such as combining artificial intelligence and big data technology, to develop personalized treatment solutions and products, in order to improve the treatment effect and user experience. The next step is to innovate and develop general equipment to achieve mass production. At the same time, we can jointly develop and promote through cooperation with other technology-related enterprises and institutions to promote new technologies and products to expand the companies technological advantage and market share.
During the 14th Five-Year Plan period, the state vigorously developed high-tech products, encouraged domestic high-tech products to become bigger and stronger, and accelerated the steady improvement of the national economy and health. The State Council and the competent government departments have issued a series of relevant industrial policies. The trend of relevant policies issued by the state to guide the trend of industrial development cannot be ignored. The following are the relevant policies collated:
China has maintained overall economic and social stability, according to the National Bureau of Statistics. In response to the impact of more than expected factors such as the repeated delay of the epidemic and the outbreak of the Ukraine crisis, we resolutely stepped up the implementation of macro policies, focused on stabilizing growth, stabilizing employment and stabilizing prices, and promoting the stabilization and recovery of the economy. In 2022, the GDP will reach 121 trillion yuan, up 3.0%; 12.06 million, and the surveyed urban unemployment rate is 5.5% at the end of the year; The overall price level continues to run smoothly, and the consumer price index (CPI) keeps below 3%, in sharp contrast to the global inflation level reaching a new high of more than 40 years.
The Ministry of Finance issued a report on the implementation of the central and local budgets for 2022 and the draft central and local budgets for 2023. The report points out that the improvement of medical and health service capacity should be supported in 2023. A total of 170 billion yuan will be allocated through general transfer payments, and 30 billion yuan will be carried forward from the accrual basis in 2022 to support local governments in epidemic prevention and control, with the focus on county-level governments. It is worth noting that the era when the middle and low-end equipment can dominate the county market only with the advantage of low price has passed. When the current attention of county medical treatment has been greatly increased, the county hospitals demand for high-end medical equipment and the requirements for product performance are also there.
It can be seen that the new medical devices have a broader demand in the industry.
1)Traditional treatment methods conflict with obvious side effects
2)The popularization of primary medical care conflicts with the shortage of this industry
In terms of policy, the state supports the independent innovation of high-tech products, attaches importance to the safety and practicability of products, and encourages the localization of drugs and the substitution of imports.
Economically, Chinas national consumption capacity is gradually enhanced, the consumption structure is constantly upgraded, the medical market is constantly expanding, and the steadily improving economic level has catalyzed the development of the medical industry.
In the society, the contradiction between the traditional treatment methods and the obvious side effects and the popularization of primary medical care and the shortage of this industry still need to be further solved.
In conclusion, the treatment of diabetes with lactic acid bacteria developed by the companys project is in an excellent macro environment.
In order to have a clear understanding of the competitive relationship between the project products and the competing products and avoid the disadvantages, this section uses the Porter five-force model (supplier bargaining power, customer bargaining power, potential entrants threat, substitute threat, industry competition degree) for analysis (Figure 2).
The supplier bargaining power of this project product is assessed as moderate. This product is composed of synthetic Lactobacillus, FGF21 plasmid, and P9 plasmid. All the bacterial strains were provided by the domestic suppliers. The number of domestic suppliers, the market price is basically unified. Internal embedded plasmids require support from Biosynthetic Inc. At present, the number of domestic biosynthetic suppliers is large, and the price is basically the same. Therefore, the production cost of this product is basically stable all the year round. With the continuous improvement of the technical manufacturing level of the team, the technical manufacturing cost may decrease in the future, which further improves the cost advantages of this project.
The bargaining power of this product is high. The target customers of this product are hospitals and biomedical companies above the county level. According to the previous social environment analysis and market survey, the total number of diabetes population in China will reach 438 million, and the incidence of the population will be 0.9%. Traditional treatment methods often bring systemic side effects, so the treatment method of lactic acid bacteria without obvious side effects is favored by most people. However, because there is no concurrent product in the domestic market, the market demand is huge. Therefore, we will have a higher bargaining power.
Potential entry threat of this product was assessed as low. Compared with other commodities, the technical content of biomedical products will be higher, and our products solve the problems of long-term monitoring and optimization of blood sugar concentration in the body, and make long-term considerations. First of all, it is difficult for foreign entrants to make breakthroughs and make innovations in technology. Secondly, with the help of the scale of the industrial chain, the threshold of entry is further raised.
This product substitute threat is assessed as low. Compared with the traditional treatment of long-term insulin injection, the best solution for diabetes is to promote the secretion of insulin and GLP-1 without obvious side effects. In the process of using biguanide drug treatment, there are great side effects, which can lead to hypoglycemia symptoms and gastrointestinal reactions. One of the principles of disease diagnosis and treatment is to reduce the harm of side effects to the body, and obviously some of the substitutes do not meet this principle.
The industry competition degree of this product is assessed as low. At present, there is no company producing similar products in the domestic market. Compared with similar drugs, our products can perform autocrine related operations and monitoring through cholate response, without blood glucose measurement, and the response is easier. Besides, our products are mainly aimed at major pharmaceutical companies and hospitals, which are more specialized than the retail model.
In conclusion, our treatment of diabetes has moderate supplier bargaining power, high bargaining power of buyers, high entry threshold for potential competitors, weak substitute threat, and high and strong competitive advantage in the domestic market. Through the five-force model analysis and trade-off, our product replaces the cholate response with the blood glucose concentration response treatment, which is non-invasive and harmless. Further build up the products uniqueness.
Synthetic lactic acid bacteria yogurt, which can be used to treat diabetes mellitus and alleviate diabetic complications. According to different treatment requirements, the company has conducted different product positioning.
Synthetic lactic acid bacteria yogurt is mainly sold to large pharmaceutical companies and clinics, and can be personalized according to the needs of patients.
The medical institution market is one of the most important markets for this project (Figure 2). With the improvement of Chinas medical level, in addition to major hospitals and clinics paying more and more attention to medical services, various medical institutions have also begun to pay attention to the construction of primary medical services, and the treatment of diabetes by synthetic lactic acid bacteria, as a product with high popularity, has a high market demand. Therefore, this project will be mainly promoted in the medical institution market.
There are a large number of people with primary diabetes, and due to limited treatment conditions, patients need long-term medication or insulin injections. The company designs generic synthetic lactic acid bacteria yogurt, does not need personalized customization, patients can take by themselves, to achieve mass production. Universal products provide convenience for the treatment of primary diabetes patients. Therefore, primary medical institutions are another advantageous market for this product.
Given the large and growing market demand for patients with diabetes, this project aims to provide new strategies for diabetes treatment. This project will focus on providing high-quality, efficient and personalized treatment options to meet the urgent needs of patients with diabetes mellitus for improving their quality of life.
The specific marketing arrangement is mainly developed from the aspects of products and prices. It is summarized in the following figure (Figure 7), and see each section for details.
Our team provides synthetic lactic acid bacteria yogurt and adopts a product portfolio strategy when actual sale.
Synthetic lactic acid bacteria yogurt adopts the asset-light operation mode of "self-development and sales, production and outsourcing". Our team occupies the high value-added value part of the industrial chain, that is, both ends of the smile curve (Figure 8).
Our team can control the quality difference caused by outsourcing through supervision and motivation. On the one hand, after receiving the entrusted processing commodities, the quality inspection link is added, and it is agreed when signing the entrusted processing contract. If there is an unusually high detection rate of defective products, the entrusted processing party shall compensate the client for the economic losses. On the other hand, coordinate the realization of the interests of the processor and the client. Three years before the establishment of the company (i. e., the development period of synthetic lactic acid bacteria yogurt), it is mainly supervised by the rotation of management personnel between related parties. After the product enters the introduction period, the client and the agent will exchange shares to further coordinate the interests of both parties.
The products provide corresponding products according to the needs of customers, and the intelligent auxiliary recognition of blood glucose concentration module is a value-added service with a long development cycle. During the development period, the mature parts will be open to customers after free development. After the development period, customers can choose some of the functions according to their own needs. Supporting software to use the sales model, the team also provides software use training services.
Before pricing, a comprehensive analysis of the costs of product research and development, production, marketing and after-sales service is needed. At the same time, future operating and maintenance costs should be considered to ensure that pricing covers all related costs with reasonable profit margins.
The lingual nerve electric stimulator product of this project has unique technical advantages and therapeutic effect, which can provide long-term and effective relief for diabetic patients. Our pricing strategy should differentiate a product from competitive products in the market based on the unique value of the product. This product is currently priced at 40 yuan for all major medical institutions and clinics. This project needs to emphasize the product innovation, personalized treatment plan, user-friendly, and long-term effects, so as to give higher value to the product.
Our team products are oriented to emerging market segments, and in terms of pricing, we need to conduct a comprehensive analysis of the cost of product research and development, production, marketing and after-sales service costs. At the same time, future operating and maintenance costs should be considered to ensure that pricing covers all related costs with reasonable profit margins. The "synthetic lactic acid bacteria yogurt" product with intelligent assisted identification requires a lot of human capital and belongs to a new generation of information technology products, with great space for development and facing a long growth period. Cost-plus pricing method is mainly adopted in pricing. At the same time, differentiated pricing strategies can be considered for different customer groups. For high-end customers, the price can be slightly higher, and personalized adjustment for the taste and proliferation efficiency of yogurt. For the mid-end customers, the requirements of yogurt are to meet the treatment conditions as the standard, and then to provide standardized treatment plans and services. For grass-roots users, universal products are adopted to reduce the complex process of seeking medical treatment and self-use. For the three types of people, we provide after-sales service. In addition, the project can also consider the launch of different models to meet the needs of different customers and distinguish between the pricing.
At present, the number of domestic pharmaceutical enterprises is large, the scale is small, and the industry concentration is very low. In addition, many foreign multinational pharmaceutical giants settle in, making the merger and reorganization of domestic pharmaceutical enterprises become an inevitable trend of development. In the continuous process of corporate restructuring and merger and acquisition, the whole market environment is full of challenges and tense atmosphere. The enterprise needs not only daily management skills, but also needs talents proficient in capital operation.
At present, the number of domestic pharmaceutical enterprises is large, the scale is small, and the industry concentration is very low. In addition, many foreign multinational pharmaceutical giants settle in, making the merger and reorganization of domestic pharmaceutical enterprises become an inevitable trend of development. In the continuous process of corporate restructuring and merger and acquisition, the whole market environment is full of challenges and tense atmosphere. The enterprise needs not only daily management skills, but also needs talents proficient in capital operation.
At present, the number of domestic pharmaceutical enterprises is large, the scale is small, and the industry concentration is very low. In addition, many foreign multinational pharmaceutical giants settle in, making the merger and reorganization of domestic pharmaceutical enterprises become an inevitable trend of development. In the continuous process of corporate restructuring and merger and acquisition, the whole market environment is full of challenges and tense atmosphere. The enterprise needs not only daily management skills, but also needs talents proficient in capital operation.
Enterprises must have accurate curative effect, safe and reliable, convenient consumer services and products as a strong backing of marketing. Therefore, the pharmaceutical industry will have a large growth space for the scientific research talents who have both medical theoretical knowledge and research and development skills.
The Labor Demand Plan is designed to ensure that the organization achieves the following objectives:
1)Obtain and maintain a certain number of personnel with specific skills, knowledge structure and capabilities; make full use of available human resources;
2)Be able to predict the potential excess personnel or insufficient manpower in the enterprise organization;
3)Build a well-trained and flexible labor force to enhance the ability of enterprises to adapt to the unknown environment;
4)Reduce enterprises dependence on external recruitment in key technical links
The existing diagnosis of human resources is the basis of the follow-up work and is an important process of human resource planning, and the accuracy of the results will have a significant impact on the accuracy of the whole human resource planning. The key to the diagnosis of existing human resources lies in the quantity, quality, structure and distribution of human resources. Human resource information should include the following aspects: 1)Personal nature situation, such as gender, age, etc.; 2)Recruitment materials, including the signing time of the employment contract, recruitment channels, work experience, foreign language types and levels, special skills, and hobbies or specialties of potential value to the enterprise; 3)Educational materials, including the degree of education, major, etc.; 4)Work execution evaluation, including the time of last evaluation, evaluation report, the original data of previous evaluation, etc.; 5)Work experience, including previous work units and departments, apprenticeship or special training materials, reasons for promotion and promotion, reasons and types of punishment, information on the last internal transfer, etc.
This step and human resource diagnosis can usually be carried out at the same time, mainly to choose the appropriate prediction method according to the development strategy planning of the enterprise and the internal and external conditions of the enterprise, and then to predict the structure, quantity and quality of human resource demand. When predicting the demand for human resources, the influence of the following factors on the quantity and quality of personnel demand; 1)Market demand, product upgrade or the enterprise decides to enter a new market or a new business model; 2)Personnel turnover rate, such as the annual rate of resignation and dismissal, personnel job-hopping rate, etc.; 3)Training arrangement planned by the enterprise; 4)Technical and organizational reforms to improve efficiency; 5)The financial budget of the enterprise.
1)Determine the personnel demand data this step is mainly to compare the predicted demand with the existing supply, to determine the quality, quantity, structure and distribution of personnel are inconsistent, so as to obtain the personnel demand data. 2)Formulate matching policies to ensure the consistency of demand and supply This step is actually to develop various specific plans and actions to fill the gap in human resource needs. It mainly includes: recruitment, training, assessment, salary, career development and basic personnel management policies, etc. Recruitment: The Human Resources Department must determine the ability to meet the development goals of the company and realize the human capital consistent with the business development of the company; clearly define the knowledge, skills and abilities that must be possessed for each position; confirm qualified internal and external applicants to realize the human and post matching; conduct talent selection and promotion according to the ability development of employees; and improve the recruitment procedures from five aspects: recruitment principles, process, channels, testing and evaluation of recruitment work. Training: Develop a career development path to update the knowledge structure of employees; provide training opportunities to enhance their business skills and industry knowledge to meet the needs of the company; encourage job rotation and cross-field training; arrange time to guide and review employees; to promote and promote the company; according to the local conditions, establish its own training course resource system and make full use of internal and external resources to realize the systematic, standardized and personalized training work.
Labor resources are an important force and significant advantage of our company in the fierce market. Firm labor force development strategy, is our company to promote high-quality development in the practical needs. Our company arranges the labor force development strategy into three stages. In the first stage, the company defines the current organization and arrangement, including 1 chairman, 1 general manager, 8 from the administration department, 2 from the general manager, 6 from the operation center, 13 from the technology research and development department, 4 from the marketing planning department and 2 from the legal department. In the second stage, the human resources department, administration Department, Finance Department, Sales Department, customer service Department, platform operation, event planning, research and development department, product design and testing department will recruit 2 more people each. In the third stage, we should stabilize the functional strategy and expand the corresponding number of people in the relevant basic departments according to the operation situation.
Quality assurance in the design stage is particularly important. If quality problems occur in the design stage, the direct loss of the project, economic loss and reputation loss of the enterprise will be inestimable. Therefore, the project in the design stage at the beginning attaches great importance to the engineering quality management and control, set up service quality management leading group, for the whole product design process for comprehensive control, formulate detailed measures of rewards and punishments, according to the stage, check the quality hidden danger found in the inspection held special analysis
Discuss, develop targeted solutions.
We monitor the quality of design products and management system through the implementation of the Resource Management Procedure, Design Process Control Procedure, Survey Process Control Procedure, Quality System Audit Procedure and Data Analysis; ensure that the designed products provided by us meet the requirements, the service quality management system is GB / T19001 / 2008 / I9001; 2008, and promote the continuous improvement of the quality management system through data analysis.
1)Attach great importance to the ideology, fully guarantee the organization, adopt the project operation system management mode, and with the support and cooperation of all departments to ensure the smooth development of the preliminary design.
2)Establish and improve the project organization, select high-quality survey with rich experience and strong sense of responsibility, design personnel to form a project team, clarify the responsibilities of each personnel, and strengthen the coordination between majors in the process of project promotion.
3)Operate according to relevant documents, strengthen prior guidance, process inspection and design review, and pay attention to the adjustment of basic data
Check, collection and the authenticity of the basic data, completes the overall design and coordination, more comprehensive comparison, to ensure that the rationality of the design scheme, feasibility, safety and economy, correctly handle the design quality and design schedule, the relationship between design quality and efficiency, the quality measures to the whole process of design.
4)In order to ensure the normal and effective operation of the project, at the beginning of the project, strengthen the site survey and prior guidance, to ensure the design quality requirements from the overall plan.
Establish long-term cooperative relations with schools of Life Sciences, medical schools and research institutes of Biotechnology of Tsinghua University, Peking University, Zhejiang University and other top domestic universities, share scientific research achievements and experimental resources, and conduct technical exchanges and joint research and development.
Cooperate with Institute of Microbiology of Chinese Academy of Sciences, Shanghai Institute of Nutrition and Health of Chinese Academy of Sciences and other national research institutions to obtain the latest scientific research results support and accelerate the research transformation process of products.
Cooperation with Junyao Runying, Bright Dairy and other enterprises with mature probiotics production technology to ensure the stable production and quality control of engineered lactic acid bacteria.
Cooperate with multinational pharmaceutical enterprises and well-known domestic pharmaceutical enterprises to jointly develop probiotic drugs or functional food, and expand market sales channels.
Policy and financial support: Actively strive for policy and financial support from national and local governments, including scientific research project funding, tax relief and other preferential policies.
Join Chinese Society of Food Science and Technology, Chinese Nutrition Society and other relevant industry associations, participate in the formulation of industry standards, obtain industry information, and strengthen exchanges and cooperation with other enterprises.
Continuous R & D investment: increase R & D investment in synthetic biology, gene editing, probiotics functional research and other fields, and constantly optimize the performance and therapeutic effect of engineered lactic acid bacteria. Technology innovation and intellectual property protection: strengthen technological innovation, apply for patent protection, and ensure the core competitiveness of enterprises.
Quality management system: establish a sound quality management system to ensure that every link in the production process complies with national and industrial standards and to ensure product quality. Supply chain management: optimize supply chain management, establish long-term and stable cooperative relationship with suppliers, and ensure the stable supply of raw materials and cost control.
Brand building: strengthen brand publicity, enhance brand awareness and reputation, and establish a professional and reliable corporate image. Market expansion: For diabetic patients and the people concerned about health, formulate precise marketing strategies, expand online and offline sales channels, and improve the market share. Customer service: establish a perfect customer service system, provide high-quality pre-sales consultation and after-sales service, and enhance customer stickiness.
Talent introduction and training: introduce professionals with synthetic biology, biotechnology, pharmaceutical research and development background, and strengthen the training and development of internal staff to improve the overall quality and innovation ability of the team.
Team building: establish an efficient team communication mechanism, encourage the cooperation and communication among team members, and form a positive working atmosphere.
Our company adopts the flat management mode, set up the general manager and the heads of each department, under 9 main departments. According to the relevant requirements of each department, the responsibilities of each person in charge and each post are also fully refined to facilitate management and tracking.
The company organization chart is as follows:
The research and development department is the core of the company innovation, mainly responsible for the development of new products and the improvement of existing products. The departments work includes technical research, product design, sample testing, technical evaluation, and the introduction and application of new technologies. Research and development departments are usually committed to innovation and technological breakthroughs based on market demand and corporate strategy to ensure that the companies products have a competitive advantage. At the same time, the R & D department is also responsible for the planning of the technical architecture to ensure that every link of the product from the design to the implementation is in line with the development direction of the company. In order to support the long-term development of the company, the R & D department is also responsible for reserving technical personnel, promoting technical cooperation, maintaining academic exchanges with both inside and outside the industry, and constantly absorbing new technologies and applying them. The success of the R & D department has a direct impact on the company technological leading position in the market. Therefore, to increase the R & D investment and optimize the technological innovation process is one of the keys to the long-term development of the company.
The production department is responsible for the actual production and manufacture of the products designed by the R & D department. The department ensures the effective operation of production equipment and technology, and completes the production tasks of products on time, in quality and in quantity. Production departments usually work closely with supply chain management to ensure the procurement of raw materials and inventory management. At the same time, the production department needs to manage the operation of the production line, maintain the equipment and ensure that each link in the production process meets the safety and environmental standards stipulated by laws and the company. Optimizing the production process, reducing waste and improving production efficiency are the core work of the department. By introducing automation and intelligent production technology, the production department can further reduce costs, improve productivity, and provide strong product supply support for the company.
The main responsibility of the quality management department is to ensure that all the products produced by the company meet the quality standards and meet the customer requirements. The department develops and implements the quality control system and supervises every link in the production process, from the inspection of raw materials to the inspection of finished products. Through continuous monitoring and analysis of product performance, the quality management department can find and solve quality problems in time to avoid unqualified products entering the market. In addition, the department needs to work with relevant certification bodies to ensure that the company production processes and products meet national and international quality standards. For the company, quality products are the basis for winning the trust of customers and competitive advantage, so the quality management department plays a vital role in maintaining and improving the companies product reputation.
The sales department is the bridge between the company and its customers, and is responsible for the marketing and sales of the companies products. The department expands the market share of the companies products by developing sales strategies, expanding the market and maintaining customer relations. The sales team needs to deeply understand customer needs, analyze market trends, and make accurate market positioning according to the characteristics of the companies products. At the same time, the sales department also cooperates with the marketing department to plan and implement online and offline promotional activities to ensure that the products can get the maximum exposure and customer recognition. Sales personnel need to have good communication skills and customer service ability, to be able to effectively deal with customer feedback and complaints, to establish a good market image for the company. Excellent sales performance is directly related to the companies revenue growth and market position, so the sales department has an important position in the overall operation of the company.
The customer service department is responsible for handling all after-sales services related to the customer, including consulting, complaints, technical support, etc. The department ensures long-term customer loyalty to the company products by providing timely and professional services to maintain and improve customer satisfaction. The customer service team not only needs to understand the companies products and services, but also has the problem-solving skills and good communication skills to quickly respond to customer needs and provide effective solutions. The work quality of the customer service department directly affects the companies image and reputation in the eyes of customers, so the department is crucial for the companies brand maintenance and customer relationship management. The collection and analysis of customer feedback also provides an important basis for the companies product improvement.
The financial department is the core department of the companies fund management, responsible for the companies daily fund operation, financial planning, cost control and the preparation of financial reports. The department makes a reasonable financial budget and monitors the flow of funds to ensure the effective use of the companies funds. The financial department is also responsible for tax planning, financial audit and other work to ensure that the company complies with relevant laws and regulations and maximizes profits through effective financial management. The department needs to work closely with other departments to ensure that the company resource allocation is in line with the company development strategy and help the company expand its business while expanding its business.
The human resources department is responsible for the company personnel management, including recruitment, training, performance appraisal, salary and welfare management, etc. The department improves staff efficiency and satisfaction by attracting and retaining talented people. The HR department also needs to develop reasonable training plans to help employees improve their skills to meet the needs of the companies development. At the same time, the human resources department is also responsible for the construction of the company culture to ensure that the companies values are implemented and implemented among the employees. Good talent management and incentive mechanism is very important for the long-term and stable development of the company.
The administrative department is the support department of the daily operation of the company, responsible for the management of the office environment, the handling of administrative affairs and the communication and coordination within the company. By managing the companies equipment, logistics, documentation and meetings, the daily work of the company is smoothly. The administrative department also needs to coordinate all kinds of external affairs, such as communication with suppliers, public relations handling, etc., and is an important maintainer of the companies external image.
The legal compliance department is responsible for ensuring that all business activities of the Company comply with the requirements of laws and regulations, and preventing and handling the legal risks that the Company may face. The department is responsible for reviewing contracts, supervising the companies compliance with industry regulations, handling its internal and external legal affairs, and ensuring the legality and compliance of the companies operations. Effective legal compliance management can reduce the potential risks of the company and ensure the long-term stability of the companies business.
We plan to expand in many ways. First of all, we will increase the research and development efforts, invest more resources to optimize the existing products, and promote the development of new products. With the dual support of online and offline channels, our company plans to increase the marketing efforts all over the country to enhance the brand awareness and influence. At the same time, our company will expand the r & d talent reserve, attract more high-level technical personnel to join, and ensure the continuous progress of technological innovation. In terms of company operation, fine management will be the key to the development of the company. By optimizing the production process and improving the efficiency, our company will maintain the cost advantage in the fierce market competition. Perfect customer service system will also help our company to expand the scale while maintaining customer satisfaction.
Good products are the core of the companys competitive advantage. In the future, our company will make concerted efforts in product research and development, marketing, production optimization and other aspects, and break the market barriers through high-quality products to achieve further expansion of the companys business.
Our company will continue to conduct technical research and pay close attention to the industry trends. Through the cooperation with universities and research institutions, to maintain the forward-looking technology.
By establishing a flexible technical architecture, we can ensure that we can respond quickly to market changes. The introduction of new technologies will help companies improve their competitiveness.
Our company will build an efficient R & D team through a combination of internal training and external recruitment. At the same time, develop a reasonable incentive mechanism to attract and retain top talents.
Our company will continue to increase the investment in research and development, to ensure that there are enough resources for technological innovation and product development every year, to maintain the market competitive advantage.
At the same time of technological innovation, we will strengthen the security system and establish a risk early warning mechanism to ensure the reliability and safety of technology application.
Through high-quality products and good customer service, our company will establish a good brand image in the market, and enhance customer awareness and trust in the brand.
The company functional strategy is to ensure the efficient coordination of all departments of the company in the operation process, and the reasonable allocation of resources, so as to support the company to achieve long-term success and stable development in the market competition. The effective operation and cooperation of various functional departments is the key to achieving the company strategic goals, so it is crucial to develop a clear functional strategy.
First, the cooperation between the R & D department and the production department is the top priority in the functional strategy. The R & D department is responsible for the design and innovation of the products, while the production department is responsible for converting these designs into marketable goods. To ensure that products are timely and efficient, functional strategies should include seamless integration between research and development and production processes, reducing the time from design to mass production. By establishing a feedback mechanism between R & D and production, we can solve possible design problems in production in time to ensure that the quality of products is consistent with innovation.
Secondly, the quality management department also plays a central role in the company functional strategy. High-quality products are the key to the company competitive advantage, and the quality management department passes through a strict quality control system to ensure that the products meet the market demand and the standards of laws and regulations. The functional strategy should include the continuous optimization of quality control, especially the introduction of more automated testing means in the production process to improve the detection efficiency and reduce the possible errors caused by human factors.
The sales department and the customer service department, as the window of the company to contact with the outside world, shoulder the responsibility of building the company brand image and improving customer satisfaction. The functional strategy should emphasize the close cooperation between the sales department and the customer service department, and maintain the long-term cooperation relationship between the company and the customers through precise market positioning and timely after-sales service. Especially in expanding the market, the market development strategy of the sales department should be complemented with the after-sales support of the customer service department to ensure that the whole customer experience from purchase to use reaches a high standard.
The functional strategy of the finance department focuses on optimizing the company resource allocation and cost control. With reasonable capital geting and monitoring, the company is able to expand its business while remaining financially sound. The finance department should work closely with various departments to ensure that the allocation of funds is consistent with the company strategic objectives. For the long-term development of the company, the financial department also needs to assume the responsibility of capital risk management, and prevent unnecessary financial losses through risk assessment and prediction.
The role of the human resources department in the functional strategy is reflected in the cultivation of talents and the establishment of the incentive mechanism. By constantly attracting and retaining high-quality talents, the company promotes technological innovation and business development. At the same time, the functional strategy should include a sound employee training system to help employees improve their skills and adapt to the rapid development of the company business. Through scientific performance appraisal and a reasonable salary system, the human resources department can motivate employees to maximize their potential and contribute to the growth of the company.
The functional strategy of the administrative department should focus on improving the internal management efficiency of the company and ensuring the good operation of the office environment. The administrative department is responsible for the company daily affairs and logistics management, to ensure the communication and coordination between various departments. The functional strategy should include optimizing administrative processes, reducing unnecessary red tape, and improving the overall operational efficiency of the company.
Finally, the role of the legal compliance department in the functional strategy is crucial. With the expansion of the company business and the rapid development of technology, compliance and legal risk management are particularly important. The functional strategy should include the formulation of a sound legal risk prevention mechanism to ensure that the company can strictly follow relevant laws and regulations in technological innovation and market expansion to avoid potential risks caused by legal problems.
The enterprise, focusing on the in-depth research and development and large-scale production of lactic acid engineering bacteria, is committed to cultivating lactic acid engineering strains with unique sugar-lowering function through cutting-edge synthetic biology technology. We have reached strategic cooperation intentions with a number of well-known leaders in the dairy and probiotics industry. We plan to jointly build a factory to jointly develop and launch a series of innovative sugar-lowering health products to meet the growing market demand for healthy food.
In the early stage of entrepreneurship, our company will fully rely on the team members profound research skills in the field of synthetic biology, the optimization experience of fermentation process and the practical accumulation of dairy processing technology to realize the efficient research and development and customized production of lactic acid engineering bacteria. At the same time, in order to quickly launch the project, we will take the way of share subscription and invite far-sighted investors to join us to jointly provide the necessary financial support for the initial operation of the company.
With the steady progress of the project and the successful listing of the product, we plan to start the follow-up financing plan according to the market demand and the development trend of the company, so as to expand the production scale, improve the technological innovation ability, and further expand the market share. In addition, we will actively explore diversified financing channels, including government subsidies, venture capital and private equity, to lay a solid financial foundation for the long-term development of the company.
The initial financing of the company is 100 million yuan, which is mainly used for sales expenses, manufacturing expenses, channel construction expenses and other operating expenses of the company (the funds are mainly used for management, capital investment and innovation in the process of drug research and development). From the second year, it will attract social investment and further develop new functional modules (the funds will be used to meet the capitalization conditions of intangible assets, and will be capitalization, and the final amortization amount will be included in the cost).
The cost of this project is estimated according to the company tax registration and trademark registration fee, scientific research equipment and computers and other office supplies, store rent and decoration expenses, communication expenses, employee salary, OEM fee, advertising and development expenses, management fees and other contents to meet the production requirements. Costs include equipment, labor, expense, and depreciation. The equipment is mainly scientific research equipment, office equipment, estimated as the fixed assets invested in scientific research; labor is mainly employee salary. Expenses include company tax registration and trademark registration fees, store rent and decoration expenses, communication expenses, logistics expenses, research and development expenses, advertising and promotion expenses, etc. Estimate according to the annual sales scale, the scale of the assets formed by the investment and the single adjustment arrangement. Depreciation expenses mainly include: equipment is depreciated at the average life of 10 years (5% as residual value rate); training expenses, construction period personnel salary, related taxes and other assets are amortized by 5 years; operating income is expected to increase by 10% per year; manufacturing expenses are calculated by 5% of the annual sales revenue; channel construction expenses are calculated at 10% of the sales revenue of the current year; management expenses are calculated at 8% of the sales revenue, and increase by 10% per year after production. The annual estimated investment (based on the forecast amount of investment) and the accounting estimate are implemented.
Important indicators: sales revenue, net profit, sales net profit.
Profit margin on sales: This ratio is the ratio of net profit to sales revenue, and is used to measure the income level of enterprise sales revenue. The higher the sales profit margin, the stronger the profitability of the enterprise. The development of the enterprise presents a good momentum, and the competitiveness of the company is constantly enhanced. By increasing the sales volume, the system update and maintenance charges, improve the proportion of technical services, and the profit margin of sales is increasing.
The financial analysis of the company is a process in which the financial situation and business performance of the company are analyzed and interpreted by the financial data of the company, and provides the basis for decision-making. By collecting, sorting out and analyzing the companys financial data, we can draw conclusions about the companys financial health status, and provide decision support and the basis for predicting the future development. The goal is to assess the companys profitability, solvency, liquidity, growth potential and value so that investors, management, creditors and other stakeholders can have a better understanding of the companys financial and operating conditions.
According to the statement forecast and the analysis of financial indicators, the net profit margin continues to grow during the forecast period, and the companys operating ability, profitability and development ability are good. For detailed analysis, see the following three financial tables (taking the year after the listing of the company as an example): balance sheet, income statement, and cash flow statement. See Appendix 6 for the three financial statements of the second and third years after listing.
Used to record and summarize the assets, liabilities and owners equity of the enterprise within a specified date. It provides an overview of the various resources (assets) owned by enterprises, as well as the debts (liabilities) assumed by enterprises to external institutions and individuals. By analyzing the balance sheet, the solvency, financial stability and capital structure of the enterprise can be evaluated.
It is used to record and summarize the cash inflow and cash outflow of the enterprise during a specific period. It reflects the cash flow generated in the operation, investment and financing activities, and helps the analysts to evaluate the cash position of the enterprise and the sustainability of the operating activities.
Also known as an income statement or an income statement. It is used to summarize the revenue, costs and profits of the enterprise over a specific period. The income statement shows the revenue the business receives after selling products or providing services, as well as the direct and indirect costs associated with those revenues.
Equity net interest rate refers to the proportional relationship between a companys net profit and shareholders equity. This indicator reflects the companys ability to use shareholders equity for net income. The higher the net interest rate of equity, the higher the income that the company brings relative to the investment, and also the stronger the profitability of the owners equity of the company. It is an important indicator in financial analysis and is used to assess the profitability and financial health of a company.
Operation capacity analysis table is an analysis report on enterprise asset management efficiency. The operating capacity index is an index used to analyze the efficiency of asset management of an enterprise. The higher the efficiency of asset management, the higher the income of the enterprise will be. Operation capacity analysis can analyze the efficiency of the asset utilization of the enterprise by calculating the relevant indicators of the capital turnover, so as to evaluate the management level and asset utilization ability of the enterprise.
Profitability analysis table is based on the balance sheet, income statement and cash flow statement, through the logical relationship between the table to build a set of index system form, can help analysis and find problems in time, so as to improve enterprise financial structure, improve the enterprise debt repayment ability, management ability, ultimately improve the profitability of the enterprise.
New service models often enter the market with legal and regulatory risks. This is because different services may involve specific legal requirements and regulatory provisions, in order to protect users rights and interests, ensure fair competition, maintain data privacy, etc. If the new form of service does not comply with the relevant legal and regulatory requirements, it may face fines, lawsuits or other legal consequences. In addition, since the new forms of services may not have clear provisions in the legal and regulatory fields, they may also face uncertainty and ambiguity. This requires service providers to actively communicate with regulators and seek clear guidance to ensure that their business operations are legal and compliant.
(1) Understand legal and regulatory requirements: thoroughly study relevant laws, regulations and regulatory policies to ensure a comprehensive understanding of the legal standards and regulations applicable to new forms of services. (2) Establish a legal team: Establish a team dedicated to legal and regulatory affairs, including legal personnel, compliance officials and regulatory experts. They can track and read legal and regulatory changes and develop coping strategies accordingly. (3) Establish a cooperative relationship with regulatory agencies: actively communicate and cooperate with relevant regulatory authorities, timely understand their requirements and expectations, and ensure that their services meet regulatory requirements. (4) Review and update contract terms: Carefully review and revise existing contract terms to ensure that the new forms of services take full account of legal and regulatory requirements and clarify the responsibilities and interests of the parties. (5) Risk assessment and management: Identify potential legal and regulatory risks, and formulate corresponding risk management plans. This includes risk warning mechanisms, internal compliance training, and compliance monitoring risk processes. (6) Seek professional legal advice: hire qualified legal advisers or teams of lawyers to provide professional legal advice and advice to ensure the compliance of new forms of services and to prevent potential legal disputes. (7) Continuous monitoring and adjustment: Regularly review and update the companys compliance policies and processes, keep pace with changes in the legal and regulatory environment, and timely adjust its response strategies.
When any new service enters the market, consumers will remain skeptical, so there is a certain failure rate of new services on the market, especially for pharmaceutical products, out of ignorance of this technology or such service, and doubts about the quality and effect of the service, they will not fully believe and use the service. This could cause services to be neglected when they first enter the market. The design, construction and evaluation of nucleic acid vaccine is a new type of service, but entering the market is not an absolute market gap, which means to replace some traditional sense of the service model. Due to the habitual cognition, it takes a certain time for consumers to understand and accept the new service mode, so there must be certain market risks in the short term. In the sales process, if the market analysis and prediction is not accurate enough, the market information is not in place, and the market situation cannot be fully understood, the price set by the service will be inappropriate, which will hinder the marketization process of the service, affect the profit of the enterprise, and is not conducive to the long-term development of the company.
(1)Do a good job in market research in the early stage: fully understand the situation of consumers, such as consumer psychology and endurance. Determine the current development direction, select a target market as the breakthrough point, formulate the corresponding marketing strategy, thus open the market, and then gradually push into the whole market field. (2) Establish a set of perfect market information feedback system: always pay close attention to the dynamics of competitors and the constantly changing market conditions, timely change and improve the marketing strategies, and set reasonable sales prices. In the case of not exceeding the ability of consumers, to develop the best plan. (3) Increase publicity: on the basis of constantly improving the marketing strategy, increase publicity, highlight the advantages of service, so that the majority of consumers can receive services psychologically and physically. (4) Connect the sales team with government agencies: improve the quality of service in all aspects, so that consumers can feel good service and guarantee, and give consumers a satisfactory consumption experience.
The development of new service projects is a long-term oriented and an activity with high-tech risk. Under the new normal, enterprise technological innovation and new product research and development should timely predict, identify, analyze and evaluate all kinds of complex and dynamic technical risks. The design, construction and evaluation of nucleic acid vaccines are highly innovative and have high technical content, but the similarity of enterprise technology and the resulting patent threat are an indicator of the risk of enterprise technological innovation, and the patent threat is an important content of the technological innovation risk of enterprises.
(1) Legal weapons: The team will make full use of the intellectual property law to ensure that the design, construction and evaluation services of nucleic acid vaccines are not simply replicated. Patent protection is an important aspect of project technical risk prevention, which is an advantage for a relatively long period of time. (2) Professionalism: Constantly improve the technical content of nucleic acid vaccine design, construction and evaluation service, constantly upgrade services, and ensure the leading service in professionalism. Strengthen the training of technical personnel and talent introduction, constantly improve the technical level and overall strength of the RESEARCH and development team, and increase the investment of research and development funds, to pay special attention to the development of industry-leading technology. (3) Confidentiality measures: First, strengthen the ideological education and training of team members to prohibit the random leakage of project innovation and creativity; second, strengthen the confidentiality system management of product technology to prevent patent leakage.
As a company based on emerging technologies, talents are crucial to the development of the company. Under the economic background of the new normal state, enterprise human resource management has problems such as imbalance of human resource allocation and lack of personnel ability training system. According to the survey, the primary factor that troubles Chinese enterprises is the human resources crisis, and 33.7% of the surveyed enterprises said that the human resources crisis has had a serious impact on their enterprises. At present, there are roughly the following talent risks: talent drain risk, talent acquisition risk, talent moral hazard, risk of talent use and maintenance, and risk of weak crisis awareness. On the basis of strengthening the concept of enterprise resource security, strengthening enterprise talent risk management is an important content of enterprise management activities.
(1) Conduct strict induction training for technology research and development and other related staff, and then enter the formal work after the training is passed. We will establish a more scientific and attractive talent training and introduction mechanism, and strengthen the training and introduction of innovative talents, especially young talents, so as to form a more reasonable talent echelon and improve the overall level of the team. (2) Establish and improve the talent recruitment system and employee work system and strictly observe it. Choosing enterprise management talents from excellent technical talents, based on the rich practical experience of new service development of excellent technical talents, is more conducive to the implementation of service innovation strategy and achieve success. (3)Expand the scope of recruitment, vigorously recruit graduates from universities across the country, provide jobs, and at the same time, on major recruitment websites such as 58 Tongcheng, 51 job, Zhaopin, Liepin, etc. Ensure the priority of talents, netism is strictly prohibited. (4) Attract excellent talents with preferential treatment, improve the incentive mechanism, and increase the incentive strength for talents, so as to achieve the effect of retaining talents, mobilizing the enthusiasm for work and stimulating the enthusiasm for innovation. And to create a good working environment and scientific research environment. The basic monthly salary of senior talents is more than 10,000 yuan, the employee five social insurance and one housing fund and holiday subsidies are essential, plus the companys quarterly bonus and full attendance award year-end bonus.
Our company can support the following three ways to complete the capital exit: bidding transfer —— share public listing (IPO), contractual transfer —— sale or repurchase, and forced transfer —— bankruptcy liquidation.
That is, the initial public offering of shares refers to the listing of the enterprise in the securities market, which is a win-win situation for the enterprise itself or the investors. After the IPO of an enterprise, the equity held by the investment institution may increase ten or dozens of times, and selling its shares in time can obtain high returns. For enterprises, in addition to the value added of the stocks held by enterprises, more important is the recognition of good business performance in the capital market, which can enable enterprises to obtain funds for further development in the securities market.
Share sale is an exit channel through which a general company or another venture capital company can acquire or merges the shares held by a venture capital firm or venture capitalists at the negotiated price. Share repurchase refers to the purchase of shares by a venture enterprise or venture entrepreneur. Investors can realize their own equity of investment projects at any time to maximize the returns of venture capital companies. And the operation is relatively simple to IPO, the cost is low, can achieve one-time withdrawal and suitable for various types of companies. It can also be used as a tool for venture capital enterprises to avoid risk.
There are various uncertainties in the operation of the enterprise. For the venture capital of the confirmed project failure, we will adopt the liquidation method as soon as possible to recover as much residual capital as possible. It is the best exit way to reduce the loss when the venture investment is unsuccessful. Of course, if the failed investment project has no other debt, or although there is a small amount of other debt, but the creditors do not investigate, then other methods can be adopted to operate, and through the negotiation of determining the distribution of the residual value of the enterprise.
Timing is very important. The timing is appropriate, and the venture capital can obtain greater returns. The enterprise will be based on the merits of the investment environment and their own development status, specific problems specific analysis.
If the company operating conditions become worse, it will merge and reorganize with other competitive companies.
If the enterprise operates improperly and makes less profit, part of the assets sold will maintain normal operation; The Company will also consider selling some assets to expand market competitiveness and seize market opportunities for new project development, development and innovation to promote the sustainable development and growth of the Company.
Once the enterprise is confirmed to lose the possibility of development or grow too slow, it will file for bankruptcy liquidation. We will try to minimize the loss of venture capital projects and guarantee the maximum economic interests of investors.
If the company encounters significant financial risks, it can sell part of the equity to ensure the maximization of interests, and the equity transfer can be completed through the acquisition and merger departments of professional institutions such as investment banks and securities companies. At present, China has established sound property rights trading institutions and systems in major cities such as Beijing, Shenzhen, Shanghai and other places. Using this effective operation platform, the company can be listed to transfer the equity to make the venture capital exit smoothly.
E-mail: pengyuoms@fmmu.edu.cn
© 2024 - Content on this site is licensed under a Creative Commons Attribution 4.0 International license.
The repository used to create this website is available at gitlab.igem.org/2024/afmui-china